{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:46:01Z","timestamp":1793159161968,"version":"4.5.0"},"reference-count":62,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"philantropic funder"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Aust N Z J Psychiatry"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To critically evaluate published and unpublished systematic reviews and meta-analyses on the safety and efficacy of methylenedioxymethamphetamine-assisted psychotherapy for post-traumatic stress disorder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Six bibliometric databases and grey literature were searched from inception to 9 May 2024 for systematic reviews on the safety and efficacy of methylenedioxymethamphetamine (MDMA)-assisted psychotherapy compared to psychotherapy alone among adults with post-traumatic stress disorder. Quality assessment using the AMSTAR-2 tool was conducted independently by two investigators.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Fourteen systematic reviews comprising 20 primary studies involving up to 353 participants were included. All reviews included studies of one-to-three sessions of 50\u2013125 mg MDMA-assisted psychotherapy (some with supplemental dosage) compared to either 25\u201340 mg of MDMA or inactive placebo with psychotherapy. Four were deemed high quality. Meta-analyses reported substantial benefits of MDMA-assisted psychotherapy in improving post-traumatic stress disorder symptoms (standardised mean difference, 0.8\u20131.3), response rate (relative risk, 1.3\u20133.5) and remission rate (relative risk, 2.3\u20132.9) compared to psychotherapy alone. However, for reviews that assessed the certainty of evidence, the evidence was rated as low to very low certainty due to high risk of bias, indirectness and imprecision. There was moderate-quality evidence that MDMA-assisted psychotherapy was associated with an increased odd of transient adverse events. However, reviews noted reliance on spontaneous rather than systematic adverse event reporting, discrepancies between adverse events reported in published studies and clinical trial registries, and a lack of long-term safety data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Four high-quality systematic reviews suggest low to very low certainty evidence for efficacy outcomes and moderate to very low quality evidence for safety outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/00048674251315642","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T23:37:18Z","timestamp":1740094638000},"page":"339-360","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":21,"title":["Safety and efficacy of methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in post-traumatic stress disorder: An overview of systematic reviews and meta-analyses"],"prefix":"10.1177","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6032-4582","authenticated-orcid":false,"given":"Alene","family":"Sze Jing Yong","sequence":"first","affiliation":[{"name":"Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzie","family":"Bratuskins","sequence":"additional","affiliation":[{"name":"Neuromedicines Discovery Centre, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musa Samir","family":"Sultani","sequence":"additional","affiliation":[{"name":"Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia"},{"name":"School of Pharmacy, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Blakeley","sequence":"additional","affiliation":[{"name":"Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1431-3852","authenticated-orcid":false,"given":"Christopher G","family":"Davey","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, The University of Melbourne, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Simon","family":"Bell","sequence":"additional","affiliation":[{"name":"Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"e_1_3_3_2_1","article-title":"GRADE evidence to decision (EtD) frameworks: A systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines","volume":"32","author":"Alonso-Coello P","year":"2017","unstructured":"Alonso-Coello P, Oxman AD, Moberg J, et al. (2017) GRADE evidence to decision (EtD) frameworks: A systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. Gaceta Sanitaria 32: 167; e161\u2013e167.","journal-title":"Gaceta Sanitaria"},{"key":"e_1_3_3_3_1","article-title":"GRADE evidence to decision (EtD) frameworks: A systematic and transparent approach to making well informed healthcare choices. 1: Introduction","volume":"353","author":"Alonso-Coello P","year":"2016","unstructured":"Alonso-Coello P, Sch\u00fcnemann HJ, Moberg J, et al. (2016) GRADE evidence to decision (EtD) frameworks: A systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ 353: i2016.","journal-title":"BMJ"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2019.109735"},{"key":"e_1_3_3_5_1","first-page":"1","article-title":"Efficacy and safety of four psychedelic-assisted therapies for adults with symptoms of depression, anxiety, and posttraumatic stress disorder: A systematic review and meta-analysis","volume":"15","author":"Bahji A","year":"2023","unstructured":"Bahji A, Lunsky I, Gutierrez G, et al. (2023) Efficacy and safety of four psychedelic-assisted therapies for adults with symptoms of depression, anxiety, and posttraumatic stress disorder: A systematic review and meta-analysis. Journal of Psychoactive Drugs 15: 1\u201316.","journal-title":"Journal of Psychoactive Drugs"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2005.03.009"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.2.214"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811221116926"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1089\/psymed.2023.0007"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20656"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-022-06221-6"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-024-01865-8"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/bs4040511"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2013.07.031"},{"key":"e_1_3_3_15_1","unstructured":"Fierce Biotech (2023) First-ever Drug Application for MDMA Finally Reaches FDA after Near 40-Year Journey. Available at: http:\/\/www.fiercebiotech.com\/biotech\/maps-pbc-files-seminal-new-drug-application-mdma (accessed 8 May 2024)."},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540261.2019.1595545"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-070849"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1101\/2023.08.17.23293955"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01525-0"},{"key":"e_1_3_3_20_1","unstructured":"Heath L Gonzales V Luloh M et al. (2022) MDMA-assisted therapy for post-traumatic stress disorder: Phase 2 evidence synthesis \u2013 A report to the UTAH psychotherapy drug task force. Available at: http:\/\/www.utah.gov\/pmn\/files\/903931.pdf (accessed 18 January 2025)."},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2021-006303"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/20008198.2020.1853379"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01200-3"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881120965915"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2021.01.039"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-020-05548-2"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-024-06665-y"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291719000436"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/16549716.2017.1322399"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/00048674221083868"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291717000708"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/13811110903478997"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.22511"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2020.1769878"},{"key":"e_1_3_3_35_1","volume-title":"Lykos Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for MDMA-Assisted Therapy for PTSD","author":"Lykos Therapeutics","year":"2024","unstructured":"Lykos Therapeutics (2024a) Lykos Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for MDMA-Assisted Therapy for PTSD. San Jose, CA: Lykos Therapeutics."},{"key":"e_1_3_3_36_1","volume-title":"Lykos Therapeutics Announces Complete Response Letter for Midomafetamine Capsules for PTSD","author":"Lykos Therapeutics","year":"2024","unstructured":"Lykos Therapeutics (2024b) Lykos Therapeutics Announces Complete Response Letter for Midomafetamine Capsules for PTSD. San Jose, CA: Lykos Therapeutics."},{"key":"e_1_3_3_37_1","volume-title":"VA Evidence-based Synthesis Program Reports. Evidence Brief: Psychedelic Medications for Mental Health and Substance Use Disorders","author":"Mackey KM","year":"2022","unstructured":"Mackey KM, Anderson JK, Williams BE, et al. (2022) VA Evidence-based Synthesis Program Reports. Evidence Brief: Psychedelic Medications for Mental Health and Substance Use Disorders. Washington, DC: Department of Veterans Affairs (US)."},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10184175"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291720000070"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01336-3"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02565-4"},{"key":"e_1_3_3_42_1","unstructured":"Mustafa R McQueen B Nikitin D et al. (2024) MDMA-assisted psychotherapy for post-traumatic stress disorder: Effectiveness and value. Available at: https:\/\/icer.org\/wp-content\/uploads\/2023\/11\/PTSD_Meeting-Agenda_Final_053024-1.pdf (accessed 18 January 2025)."},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2021.1933434"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.11.007"},{"key":"e_1_3_3_45_1","first-page":"254","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Pollock M","year":"2020","unstructured":"Pollock M, Fernandes RM, Becker LA, et al. (2020) Chapter V: Overviews of reviews. In: Higgins JPT, Thomas J, Chandler J, et al. (eds) Cochrane Handbook for Systematic Reviews of Interventions (Version 6.5). London: Cochrane, p. 254."},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.2632"},{"key":"e_1_3_3_47_1","article-title":"AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea BJ","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al. (2017) AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 358: j4008.","journal-title":"BMJ"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2018.03.011"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109165"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291716001914"},{"key":"e_1_3_3_51_1","article-title":"The efficacy of MDMA (3,4-methylenedioxymethamphetamine) for post-traumatic stress disorder in humans: A systematic review and meta-analysis","volume":"13","author":"Tedesco S","year":"2021","unstructured":"Tedesco S, Gajaram G, Chida S, et al. (2021) The efficacy of MDMA (3,4-methylenedioxymethamphetamine) for post-traumatic stress disorder in humans: A systematic review and meta-analysis. Cureus 13: e15070.","journal-title":"Cureus"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100727"},{"key":"e_1_3_3_53_1","volume-title":"Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists","author":"Therapeutic Goods Administration","year":"2023","unstructured":"Therapeutic Goods Administration (2023a) Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists. Woden, ACT, Australia: Therapeutic Goods Administration, Department of Health and Aged Care."},{"key":"e_1_3_3_54_1","unstructured":"Therapeutic Goods Administration (2023b) Update on MDMA and psilocybin access and safeguards from 1 July 2023. Woden ACT Australia Therapeutic Goods Administration Department of Health and Aged Care."},{"key":"e_1_3_3_55_1","unstructured":"US Food and Drug Administration (2024) June 4 2024 Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC). Youtube. Available at: http:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/updated-meeting-time-and-public-participation-information-june-4-2024-meeting-psychopharmacologic (accessed 18 January 2025)."},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1177\/20451253231198466"},{"key":"e_1_3_3_57_1","volume-title":"Mental Health Prevalence: Mental Health and Wellbeing Transition Study","author":"Van Hooff M","year":"2018","unstructured":"Van Hooff M, Lawrence-Wood E, Hodson S, et al. (2018) Mental Health Prevalence: Mental Health and Wellbeing Transition Study. Canberra, ACT, Australia: Department of Defence and the Department of Veterans\u2019 Affairs."},{"key":"e_1_3_3_58_1","first-page":"27","article-title":"Defining response and nonresponse to posttraumatic stress disorder treatments: A systematic review","author":"Varker T","year":"2020","unstructured":"Varker T, Kartal D, Watson L, et al. (2020) Defining response and nonresponse to posttraumatic stress disorder treatments: A systematic review. Clinical Psychology: Science and Practice 27.","journal-title":"Clinical Psychology: Science and Practice"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2020.1817639"},{"key":"e_1_3_3_60_1","unstructured":"Veritas Health Innovation (n.d.) Veritas Health Innovation Covidence systematic review software. Melbourne VIC Australia: Veritas Health Innovation."},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.12r08225"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1017\/S003329172100163X"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1037\/cns0000237"}],"container-title":["Australian &amp; New Zealand Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00048674251315642","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00048674251315642","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00048674251315642","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:57:57Z","timestamp":1777373877000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00048674251315642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1177\/00048674251315642"],"URL":"https:\/\/doi.org\/10.1177\/00048674251315642","relation":{},"ISSN":["0004-8674","1440-1614"],"issn-type":[{"value":"0004-8674","type":"print"},{"value":"1440-1614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]}}}